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Authors' Reply 
We would like to thank Dr Munro for the interest he 
has shown in our paper I and for his comments. We 
are sure that Dr Munro is aware that an increasing 
number of institutions are using duplex ultrasound as 
the single independent preoperative t st; on the other 
hand, non-selective digital subtraction arch angio- 
graphy, which is safer than selective views, lacks the 
detail that is needed, particularly in unclear cases. 
In order to be reliable, duplex ultrasonography 
should be performed on good quality equipment, by 
qualified personnel and the duplex criteria for iden- 
tifying critical stenosis hould be validated. The lack 
of these points has probably contributed to the poor 
correlation between duplex ultrasonography reported 
in some multicentre trials such as NASCET. 2 
The 33 min time saving that we recorded and re- 
ported in Table 1, employing regional anaesthesia, is 
clearly explained by the fact that the patient doesn't 
need to be awakened and extubated at the end of the 
procedure and that the anaesthesiologist may perform 
the anaesthetic block in a different room while the 
operating room is cleaned up and prepared for the 
next procedure. Similarly we perform most of our 
peripheral and phlebologic procedures under epidural 
or spinal anaesthesia with a significantly increased 
number of cases per operating session. We think that 
this policy should be highly recommended to all 
centres in which this anaesthetic skill is available. 
Our definition of intensive care unit is indeed the 
standard one, and this facility was available every 
time but was required very seldom in this series. As 
we stated in the patients and methods ection, all our 
patients are monitored (with two lead ECG-D2, V5-, 
pulsed arterial pressure and continuous SpO2) in the 
immediate postoperative period for at least 3h. We 
assume that a careful nerve-sparing dissection, an 
accurate reconstruction of the carotid bifurcation, the 
greater haemodynamic stability that is granted by 
regional anaesthesia, s the ability to detect from the 
history and the perioperative behaviour the patients 
at greater isk for haemodynamic instability and the 
presence of skilled staff on the surgical ward may 
all play a role, besides fortune, in the prevention of 
untoward postoperative events. 
As far as the total length of stay is concerned, we 
do agree that a 5-day stay is still too long; in particular 
our preoperative stay is far too long. We stated in the 
Discussion section that ideally the patient could be 
admitted on the same day of surgery. We are working 
on this and we commend the centres that already 
reduced the total stay to 2-3 days. Interestingly, McCol- 
lure et al. 4 recently reported that the mean hospital 
stay in 709 patients undergoing carotid surgery in the 
U.K. and Ireland under 59 different surgeons was 7.1 
days (1-91). As Fig. 1 demonstrates, it took us a few 
years to lower the postoperative stay down to 2 days. 
Further shortening is an even slower process; ac- 
cording to our protocol in 1995 we were able to send 
patients home on the first postoperative day in less 
than half of the cases. 
The indication for carotid surgery in asymptomatic 
patients is a very interesting topic that has been ad- 
dressed in a large number of papers and that will 
still be much discussed until unequivocal data are 
available. McCollum 4 reported that British surgeons, 
who are considered rather conservative in this respect, 
operated 8.1% of their patients with asymptomatic 
stenosis, 8.9% with controlateral symptoms and 2.4% 
with vertebro-basilar symptoms. Unfortunately this 
topic has little to do with our paper. We do agree with 
Dr Munro that patients should be selected with the 
utmost attention; in particular each surgeon should be 
aware of his own results when suggesting a procedure 
especially to an asymptomatic patient. Our mortality 
and morbidity rate in asymptomatic patients is well 
below 1%, we would probably be even more cautious 
in considering this indication if our complication rate 
was higher. 




I note with interest the recent case report by I. V. Mohan 
and colleagues regarding hyperhomocysteinaemia and 
aneurysm formation. 1 My recent presentation at the 
Surgical Research Society demonstrated a significant 
relationship between hyperhomocysteinaemia and ab- 
dominal aortic aneurysms. 2 The age-matched control 
group gave a reference range for total fasting homo- 
cysteine of 8.86-14.25 ~tmol/1 using high performance 
liquid chromatography with electrochemical detection. 
In 14 patients with isolated abdominal aortic an- 
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eurysms and no clinical evidence of other vascular 
disease we found 11 (79%) with hyperhomo- 
cysteinaemia (homocysteine >14.25~tmol/1). To date 
we have found no significant difference in B12 and 
folate levels in these patients. Results for the methylene 
tetrahydrofolate reductase transition are awaited. Pre- 
vious studies have found hyperhomocysteinaemia in 
up to 39% of patients with vascular disease s but not 
in aneurysmal disease. In addition to the anecdotal 
reports and further references quoted in this case 
report, recent work has demonstrated the induction 
of a serine elastase by homocysteine l nding additional 
evidence to the putative role of homocysteine in an- 
eurysm formation. 4 
What seems surprising is that relatively modest 
increases in plasma homocysteine seem to be so sig- 
nificant, as demonstrated by a three-fold increase in 
myocardial infarction, s The problem remains not only 
in understanding how homocysteine causes vascular 
disease, but in its relevance. It is now almost 30 years 
since homocysteine was first implicated in vascular 
disease. Numerous studies have established it as a 
risk factor which is modifiable, yet despite the ease 
with which homocysteine l vels can be lowered by 
dietary supplementation, we have no long-term pro- 
spective data on the influence of homocysteine low- 
ering treatment on progression of vascular disease. 
Such a study would answer the question about the 
possibility of managing small aneurysms with vitamin 
supplementation. Furthermore, studies on the mech- 
anism of homocysteine induced vascular damage 
using a reproducible in vitro model are required to 
elucidate the role of homocysteine in atherogenesis. 
S. Caldwell  
Birmingham, U.K. 
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Rifampicin-Soaked Grafts 
Sir, 
We read with interest the article by Torsello and Sand- 
man regarding the use of antibiotic-bonded grafts in 
vascular graft infection. They show that the in situ 
technique using a rifampin-bonded graft can be an 
effective strategy with good mid-term results. After a 
mean follow-up of 33 months, only one recurrence 
and one death by sepsis was found among 12 patients 
treated with a gelatin-coated Dacron prosthesis soaked 
with rifampin (60mg/ml). Recent clinical and ex- 
perimental studies have suggested an expanded role 
for an antibiotic-bonded vascular prosthesis in the 
treatment of established graft infections, particularly 
when the graft is impregnated with gelatin or collagen, 
leading to drug accumulation and prolonged release. 
Despite the use of different concentrations of rifampin 
in which grafts have been immersed (ranging from 
lmg/ml  to 60mg/ml), this procedure has been as- 
sociated with excellent results in animal models 24 and 
in some sporadic linical cases. Until now 16 patients 
receiving antibiotic-bonded grafts for vascular in- 
fections have been reported3 -s Although the simplicity 
of this bonding technique greatly enhances its clinical 
applicability, our experience suggests that the use of 
in situ replacement of infected vascular prosthesis with 
rifampin-soaked vascular grafts does not avoid the 
risk of recurrent infections. 
Between 1993 and 1995, five patients with vascular 
infections were treated using rifampin-soaked Dacron 
grafts at our institution. For impregnation, the grafts 
were soaked in a saline solution containing 600rag 
rifampin (2mg/ml) at room temperature for at least 
15 rain before the implantation. Two patients had 
infected aortic aneurysms. One of them had a piece 
of a coronary catheter embedded into thrombus and 
aortic wall 3 years before. Because of suspected in- 
fection, a collagen-sealed graft (Hemashield; Meadox 
Medicals, Inc., Oakland, NJ, U.S.A.) was soaked with 
rifampin before the implantation. Cultures from the 
catheter, thrombus and aortic wall grew Staphylococcus 
epidermidis. ACT scan at 48 months showed no evi- 
dence of residual infection, and the patient did well 
after surgery. The other patient underwent emergency 
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